Literature DB >> 7459257

Hepatic and renal function in rats receiving immunotherapeutic doses of cyclosporin A.

P H Whiting, A W Thomson, I D Cameron, J G Simpson.   

Abstract

Adult Sprague--Dawley rats were given either 25 or 50 mg/kg cyclosporin A (Cy A) orally every 48 h during the course of an immune response to sheep red blood cells (SRBC). A profound reduction in serum haemagglutinin titres was observed at 7 and 14 days only in animals given 50 mg. Apart from a small transient elevation in transaminase levels there were no serological indications of impaired hepatic or renal function at either dose of Cy A. There was also no increase in urinary NAG (N-acetyl-beta-D-glucosaminidase) levels, indicating the absence of damage to renal tubular cells. These observations are consistent with the normal histological and ultrastructural findings in liver and kidney in this study.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7459257      PMCID: PMC2041613     

Source DB:  PubMed          Journal:  Br J Exp Pathol        ISSN: 0007-1021


  18 in total

1.  Cyclosporin A: an immunosuppressive agent preferentially active against proliferating T cells.

Authors:  D J White; A M Plumb; G Pawelec; G Brons
Journal:  Transplantation       Date:  1979-01       Impact factor: 4.939

2.  [Cyclosporin A, a Peptide Metabolite from Trichoderma polysporum (Link ex Pers.) Rifai, with a remarkable immunosuppressive activity].

Authors:  A Rüegger; M Kuhn; H Lichti; H R Loosli; R Huguenin; C Quiquerez; A von Wartburg
Journal:  Helv Chim Acta       Date:  1976       Impact factor: 2.164

3.  Comparative study of in vitro and in vivo drug effects on cell-mediated cytotoxicity.

Authors:  J F Borel
Journal:  Immunology       Date:  1976-10       Impact factor: 7.397

4.  Cardiac-allograft survival in primates treated with cyclosporin A.

Authors:  S W Jamieson; N A Burton; C P Bieber; B A Reitz; P E Oyer; E B Stinson; N E Shumway
Journal:  Lancet       Date:  1979-03-10       Impact factor: 79.321

5.  Cyclosporin A: in vivo and in vitro suppression of rat T-lymphocyte function.

Authors:  J J Burckhardt; B Guggenheim
Journal:  Immunology       Date:  1979-04       Impact factor: 7.397

6.  Effects of the new anti-lymphocytic peptide cyclosporin A in animals.

Authors:  J F Borel; C Feurer; C Magnée; H Stähelin
Journal:  Immunology       Date:  1977-06       Impact factor: 7.397

7.  Serum and urine N-acetyl-beta-D-glucosaminidase in diabetics on diagnosis and subsequent treatment, and stable insulin dependent diabetics.

Authors:  P H Whiting; I S Ross; L Borthwick
Journal:  Clin Chim Acta       Date:  1979-03-15       Impact factor: 3.786

8.  Cyclosporin A in patients receiving renal allografts from cadaver donors.

Authors:  R Y Calne; D J White; S Thiru; D B Evans; P McMaster; D C Dunn; G N Craddock; B D Pentlow; K Rolles
Journal:  Lancet       Date:  1978 Dec 23-30       Impact factor: 79.321

9.  Cyclosporin A for the treatment of graft-versus-host disease in man.

Authors:  R L Powles; A J Barrett; H Clink; H E Kay; J Sloane; T J McElwain
Journal:  Lancet       Date:  1978 Dec 23-30       Impact factor: 79.321

10.  Extensive prolongation of rabbit kidney allograft survival after short-term cyclosporin-A treatment.

Authors:  C J Green; A C Allison
Journal:  Lancet       Date:  1978-06-03       Impact factor: 79.321

View more
  2 in total

1.  Experimental cyclosporin A nephrotoxicity.

Authors:  P H Whiting; A W Thomson; J T Blair; J G Simpson
Journal:  Br J Exp Pathol       Date:  1982-02

2.  Renal injury induced by long-term administration of cyclosporin A to rats.

Authors:  T Bertani; N Perico; M Abbate; C Battaglia; G Remuzzi
Journal:  Am J Pathol       Date:  1987-06       Impact factor: 4.307

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.